Immunohistochemical Profile and Clinical-Pathological Variants of Breast Cancer in Northeastern Mexico


  • Jose Manuel Ornelas-Aguirre Hospital de Especialidades No. 2, Unidad Médica de Alta Especialidad. Centro Médico Nacional del Noroeste del Instituto Mexicano del Seguro Social en Cd. Obregón, Sonora, México
  • Laura Maria de la Asunción Perez-Michel Oncology Department, Hospital de Especialidades del Grupo Médico San José en Cd. Obregón, Sonora, México



Breast cancer, HER2/neu, estrogen receptor, progesterone receptor, immunohistochemistry.


 Background: Breast cancer is a heterogeneous illness, with subtypes of varying etiology. Estrogen Receptor (ER), Progesterone Receptor (PR) and HER2/neu (Human Epidermal Growth Factor Receptor 2) expressions have been identified as predicting factors.

Objective: To demonstrate the possible association of the five immunohistochemical (IHC) expression profiles with clinical and histopathological variables of breast cancer in northeastern Mexico.

Methodology: In 522 women with breast carcinoma, five IHC profiles were defined [Luminal A, Luminal B, Mixed, HER2/neu and Triple-negative (TN)]. An analysis was done to determine if there were differences between them in relation to the clinical and histopathological variables.

Results: The distribution of the histological subtypes was: luminal A (32.97%), TN (27.53%), HER2/neu (19.02%), mixed (13.41%) and luminal B (7.07%). The average age at diagnosis was 53.07 ± 12.08 years, in 90.5% of the patients the size of the tumor was ≥ 2.0 cm, and 40.94% had lymph node involvement. Luminal A subtype had the highest percentage in the postmenopausal state (63.7%, p=0.071). Illness recurred in 21.01% of the patients (n=116), principally with the TN subtype (28.3%, p=0.012).

Conclusions: This study detected the characterization of IHC subgroups in patients treated for breast cancer at a reference center for cancer treatment in northeastern Mexico.


Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.

Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-17.

Rodríguez-Cuevas S, Macías C, Labastida S. Breast cancer in Mexico: young women's disease? Ginecol Obst Méx 2000; 68: 185-90.

Rodríguez-Cuevas S, Capurso-García M. Epidemiology of breast cancer. Ginecol Obst Méx 2006; 74: 585-93.

Perou CM, Sorlie T, Eisen MB, van de Run M, Jeffrey SS, Rees CA. Molecular portraits of human breast tumors. Nature 2000; 406: 747-52.

Espinosa E, Gámez-Pozo A, Sánchez-Navarro I, Pinto A, Castañeda CA, Ciruelos E, et al. The present and future of gene profiling in breast cancer. Cancer Metastasis Rev 2012; 31: 41-46.

Kaufmann M, Pusztai L, and the Biedenkopf Expert Panel Members. Use of standard markers and incorporation of molecular markers into breast cancer therapy: Consensus recommendations from an International Expert Panel. Cancer 2011; 117: 1575-82.

Reis-Filho JS, Westbury C, Pierga JY. The impact of expression, profiling on prognostic and predictive testing in breast cancer. J Clin Pathol 2006; 59: 225-31.

Viale G, Mastropasqua MG. What can the pathologist offer for optimal treatment choice? Ann Oncol 2010; 21(Suppl 7): 27-29.

Haibe-Kains B, Desmedt C, Loi S, Culhane AC, Bontempi G, Quackenbush J, et al. A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst 2012; 104: 311-25.

Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011; 378: 1812-23.

Williams JL. Malignancy: an evolving definition of a cancer cell. Clin Lab Sci 2002; 15: 37-43.

Folkman J, Ryeom S. Is oncogene addiction angiogenesis-dependent? Cold Spring Harb Symp Quant Biol 2005; 70: 389-97.

Hodes R. Molecular targeting of cancer: telomeres as targets. Proc Natl Acad Sci USA 2001; 98: 7649-51.

Arrechea-Irigoyen MA, Vicente-Garcia F, Cordoba-Iturriagagoitia A, Ibañez-Beroiz B, Santamaria-Martinez M. Molecular subtypes of breast cancer: prognostic implications and clinical and immunohistochemical characteristics. An Sist Sanit Navar 2011; 34: 219-33.

Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R, et al. A divergent for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study. Breast Cancer Res 2008; 10: R74.

Ludovini V, Gori S, Colozza M, Pistola L, Rulli E, Floriani I, et al. Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Ann Oncol 2008; 19: 883-90.

Ayadi L, Khabir A, Amouri H, Karray S, Dammak A. Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma. World J Surg Oncol 2008; 6: 112-19.

Dowsett M, Houghton J, Iden C, Salter J, Farndon J, Ahern R, et al. Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according to estrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 2006; 17: 818-26.

Jelovac D, Wolff AC. The adjuvant treatment of HER2-positive breast cancer. Curr Treat Options Oncol 2012; 13: 230-39.

Eroles P, Bosch A, Alejandro Pérez-Fidalgo J, Lluch A. Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways. Cancer Treat Rev 2012; 38: 698-707.

García-Fernández A, Giménez N, Fraile M, González S, Chabrera C. Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. A single institution survey spanning 1998 to 2010. Breast 2012; 21: 366-73.

Bauer K, Parise C, Caggiano V. Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer. BMC Cancer 2010; 10: 228.

Ellis MJ, Tao Y, Luo J, A’Hern R, Evans DB. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008; 100: 1380-88.

Guedj M, Marisa L, de Reynies A, Orsetti B, Schiappa R. A refined molecular taxonomy of breast cancer. Oncogene 2012; 3: 1196-206.

Yong-Seok K, Won YS, Park KS, Song BJ, Kim JS. Prognostic significance of HER2 gene amplification according to stage of breast cancer. J Korean Med Sci 2008; 23: 414-20.

Arnedos M, Bihan C, Delaloge S, Andre F. Triple-negative breast cancer: are we making headway at least? Ther Adv Med Oncol 2012; 4: 195-10.

Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008; 14: 1368-76.

Bloom HJ, Richardson WW. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359-77.

Sobin LH, Wittekind Ch. TNM classification of malignant tumors. 6th ed. New York, NY: Willey-Lliss 2002.

Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE. Subtyping of breast cancer by immunohistochemestry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. Plos Med 2010; 7: e1000279.

Ryu DW, Jung MJ, Choi WS, Lee CH. Clinical significance of morphologic characteristics in triple negative breast cancer. J Korean Surg Soc 2011; 80: 301-306.

Lin C, Chien S, Che L, Kuo S, Chang T, Chen D. Triple negative breast carcinoma is a prognostic factor in Taiwanese women. BMC Cancer 2009; 9: 192.

Akasbi Y, Bennis S, Abbass F, Znati K, Joutei KA. Clinicopathological, therapeutic and prognostic features of the triple-negative tumors in moroccan breast cancer patients (experience of Hassan II university hospital in Fez). BMC Res Notes 2011; 4: 500.

Rhee JR, Han S, Oh D, Kim JH, Im S. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer 2008; 8: 307.

Chacón RD, Costanzo MV. Triple-negative breast cancer. Breast Cancer Res 2010; 12(Suppl 2): S3.

Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007; 109: 1721-28.

Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007; 25: 1239-46.

Perez-Michel LM, Gonzalez-Lizarraga M, Ornelas-Aguirre JM. Recurrence of breast cancer among women of Northwest Mexico. Cir Ciruj 2009; 77: 177-83.

Sandoval-Hermosillo F, Vázquez-Lara GA, Farias-Evangelista LD, Madrid-Venegas DC, Jimenez-Covarrubias MG. Comparing two diagnostic methods used for breast neoplasm in a cancer centre in Colima, Mexico. Rev Salud Publica 2010; 12: 446-53.

Field TS, Buist DSM, Doubeni C, Enger S, Fouayzi H. Disparities and survival among breast cancer patients. J Natl Cancer Inst Monogr 2005; 35: 88-95.

Park HS, Kim S, Kim K, Byung HY, Chae BJ. Pattern of distant recurrence according to the molecular subtypes in Korean women with breast cancer. World J Surg Oncol 2012; 10(4): 2-7.

Piñero-Madrona A, Polo-García L, Alonso-Romero JL, Salinas-Ramos J, Canteras-Jordana M. Immunohisto-chemical characterisation of breast cancer: towards a new clasification? Cir Esp 2008; 84: 138-45.

Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic Markers in triple-negative breast cancer. Cancer 2007; 109: 25-32.

Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006; 19: 264-71.

Weigman VJ, Chao HH, Shabalin AA, He X, Parker JS, Nordgard SH, et al. Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat 2012; 133: 865-80.

Li CI, Malone KE, Daling JR. Differences in Breast Cancer Hormone Receptor Status and Histology by Race and Ethnicity among Women 50 Years of Age and Older. Cancer Epidemiol Biomarkers Prev 2002; 11: 601-607.




How to Cite

Jose Manuel Ornelas-Aguirre, & Laura Maria de la Asunción Perez-Michel. (2013). Immunohistochemical Profile and Clinical-Pathological Variants of Breast Cancer in Northeastern Mexico . Journal of Analytical Oncology, 2(2), 69–80.